Vaccine for prophylaxis and immunotherapy, Brazil

Genaro, Odair; Toledo, Vicente de Paulo Coelho Peixoto de; Costa, Carlos Alberto da; Hermeto, Marco Victor; Afonso, Luís Carlos Crocco; Mayrink, Wilson

doi:10.1016/0738-081x(96)00040-5

Cited by 62 publications

(47 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The antigens were injected subcutaneously at a daily dose of 0.5 ml, during three 10-day courses with 10-day intervals. Initially, increasing doses from 0.1 ml up to 0.5 ml were used during the first five days, followed by a 0.5 ml dose during the last five days (Genaro et al 1996). Antimonial therapy (15mg Sb 5+ /Kg of body weight of N-methyl glucamine) (Glucantime ® , Rhodia) was administrated concomitantly with immunotherapy.…”

Section: Methodsmentioning

confidence: 99%

“…Convit et al (1987), Mayrink et al (1992) and Genaro et al (1996) have shown that immunotherapy with subcutaneous injections of whole killed promastigote antigens, associated or not with BCG, have produced healing of lesions in human ATL, even in drug resistant patients. In this particular patient, remission of lesions was achieved after combined immunochemotherapy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Atypical Mucocutaneous Leishmaniasis Caused by Leishmania braziliensis in an Acquired Immunodeficiency Syndrome Patient: T-cell Responses and Remission of Lesions Associated with Antigen Immunotherapy

Da‐Cruz

Filgueiras

Coutinho

et al. 1999

Mem. Inst. Oswaldo Cruz

Self Cite

View full text Add to dashboard Cite

An atypical case of acquired immunodeficiency syndrome-associated mucocutaneous lesions due toLeishmania braziliensis is described. Many vacuolated macrophages laden with amastigote forms of the parasite were found in the lesions. Leishmanin skin test and serology for leishmaniasis were both negative. The patient was resistant to therapy with conventional drugs (antimonial and amphotericin B). Interestingly, remission of lesions was achieved after an alternative combined therapy of antimonial associated with immunotherapy (whole promastigote antigens). Peripheral blood mononuclear cells were separated and stimulated in vitro with Leishmania antigens to test the lymphoproliferative responses (LPR). Before the combined immunochemotherapy, the LPR to leishmanial antigens was negligible (stimulation index -SI=1.4). After the first course of combined therapy it became positive (SI=4.17). The antigen responding cells were predominantly T-cells (47.5%) most of them with CD8 + phenotype (33%). Very low CD4 + cells (2.2%) percentages were detected. The increased T-cell responsiveness to leishmanial antigens after combined therapy was accompanied by interferon-γ (IFN-γ) production as

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Atypical Mucocutaneous Leishmaniasis Caused by Leishmania braziliensis in an Acquired Immunodeficiency Syndrome Patient: T-cell Responses and Remission of Lesions Associated with Antigen Immunotherapy

Da‐Cruz

Filgueiras

Coutinho

et al. 1999

Mem. Inst. Oswaldo Cruz

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immunochemotherapy (vaccine with antileishmanial drugs) is maybe an alternative treatment for those patients for whom SbV compounds are not indicated, clinical trial guidelines are being generate 7,11,16,28 .…”

Section: Discussionmentioning

confidence: 99%

“…This complex provides substantial benefits to the patient, including the reduction of outpatient visits, and ambulatory expenses, over standard therapy 7,11,28 .…”

mentioning

confidence: 99%

Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment

Vélez

Colmenares

Muñoz

2009

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

SUMMARYVisceral leishmaniasis (VL) affects over 500 000 people worldwide each year. The disease occurs in the Mediterranean basin, Central and South America and is caused by Leishmania infantum (syn L. chagasi). VL is an endemic disease in Colombia, particularly along the Caribbean coast and the Magdalena River Valley and 90% of VL cases occur in children under the age of five. The first line of treatment is chemotherapy with pentavalent antimonial compounds, including sodium stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®). These compounds are the ones most used in Colombia, at a dose of 20 mg/kg/day for 28 days. Nevertheless resistance of L. infantum to pentavalent antimonials is becoming an important problem.No cases of VL resistant to pentavalent antimonial compounds have previously been reported from Colombia. This report describes the two cases of VL resistance to antimonial compounds in a girl and a boy who did not respond to previous treatment with Pentacarinat® and Glucantime® regimens but were treated successfully with liposomal amphotericin B. Based on our findings, we recommend liposomal amphotericin B as the first line of treatment for VL due to its low toxicity, shorter administration period and the low price obtained by WHO.

show abstract

“…A primeira vacina contra leishmaniose foi desenvolvida por Adler da (Greenblatt, 1980;Senekji & Beattie, 1941 (Genaro et al, 1996). Essa vacina acabou sendo simplificada pelo uso de uma única espécie e está sendo usada aqui no Brasil como um adjuvante durante o tratamento contra a leishmaniose (Machado-Pinto et al, 2002) após ter sido aprovada pelo Ministério da Saúde.…”

Section: -O Desenvolvimento De Vacinas Contra Leishmanioseunclassified

Microesferas lipídicas encapsuladas com proteínas antigênicas da membrana de Leishmania amazonensis com potencial aplicação terapêutica

Santos¹

View full text Add to dashboard Cite

Vaccine for prophylaxis and immunotherapy, Brazil

Cited by 62 publications

References 16 publications

Atypical Mucocutaneous Leishmaniasis Caused by Leishmania braziliensis in an Acquired Immunodeficiency Syndrome Patient: T-cell Responses and Remission of Lesions Associated with Antigen Immunotherapy

Atypical Mucocutaneous Leishmaniasis Caused by Leishmania braziliensis in an Acquired Immunodeficiency Syndrome Patient: T-cell Responses and Remission of Lesions Associated with Antigen Immunotherapy

Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment

Microesferas lipídicas encapsuladas com proteínas antigênicas da membrana de Leishmania amazonensis com potencial aplicação terapêutica

Contact Info

Product

Resources

About